Qadeer Amatullah Sana, Meher Ananda, Rachel Jennifer, Paulson Winnie, Patra Abhilash, Gandhi Naline, Ay Nirupama, Nanda Lipika, Rout Sarit Kumar, Dutta Ambarish
Indian Institute of Public Health-Hyderabad, Institute of Public Health Sciences, Hyderabad, India.
Kalinga Institute of Industrial Technology University, Bhubaneswar, Odisha, India.
Pharmacoecon Open. 2025 Mar;9(2):217-229. doi: 10.1007/s41669-024-00541-3. Epub 2024 Dec 2.
This study is an economic evaluation of total knee replacement (TKR) in comparison with non-surgical management in India.
Cost-utility analysis and budget impact analysis (BIA) were conducted on individuals aged ≥ 50 years with osteoarthritis of the knee (OA knee) Kellgren-Lawrence grades 2 and 3 using a provider's perspective. Three scenarios were considered, varying the age at which TKR is administered while assuming a 20-year lifespan for the implant. A Markov model was used to determine incremental cost-effectiveness ratios (ICERs). Sensitivity analysis was conducted incorporating implant costs and other input parameters.
Net quality-adjusted life-years (QALYs) gained per OA knee treated with TKR were superior when performed at the age of 50, regardless of OA severity and across all scenarios. The lowest ICER was 36,107 Indian National Rupees (INR) (USD 482.9)/QALY gained, observed at 50 years, while the highest was INR 61,363 (USD 820.72)/QALY gained at 70 years for grade-2 severity. Sensitivity analysis revealed that the ICER was most sensitive to the cost of non-surgical management, health utility values gained in an improved state, and the cost of TKR across scenarios. For the BIA in Scenario 1, with 40% coverage for TKR, costs reach INR 5013 crores (cr) (USD 670,477,060) in 2023 and INR 8444 cr (USD 1,024,628,736) in 2028 (1% of government budgets). In Scenario 2 (full coverage), costs are INR 12,532 cr (USD 1,520,683,008) (2.7%) in 2023, declining to 2.4% in 2028. In Scenario 3, covering 40% under the National Health Mission (NHM), costs vary from 17% in 2023 to 25% in 2028.
This study concludes that TKR is a cost-effective treatment option compared with non-surgical management for OA knee in India, irrespective of age, implant types, and severity.
本研究是对印度全膝关节置换术(TKR)与非手术治疗进行的经济学评估。
从医疗服务提供者的角度,对年龄≥50岁、患有膝关节骨关节炎(OA膝关节)且Kellgren-Lawrence分级为2级和3级的患者进行成本效用分析和预算影响分析(BIA)。考虑了三种情景,在假设植入物使用寿命为20年的情况下,改变进行TKR的年龄。使用马尔可夫模型确定增量成本效益比(ICER)。进行敏感性分析,纳入植入物成本和其他输入参数。
无论OA严重程度如何,在所有情景下,50岁时进行TKR治疗的每个OA膝关节获得的净质量调整生命年(QALY)均更高。最低的ICER为36,107印度卢比(INR)(482.9美元)/获得的QALY,在50岁时观察到,而最高的为61,363印度卢比(820.72美元)/获得的QALY,在70岁时针对2级严重程度。敏感性分析表明,ICER对非手术治疗成本、改善状态下获得的健康效用值以及各情景下的TKR成本最为敏感。对于情景1中的BIA,TKR覆盖率为40%时,2023年成本达到5013亿印度卢比(cr)(6.7047706亿美元),2028年达到8444亿印度卢比(10.24628736亿美元)(占政府预算的1%)。在情景2(全覆盖)中,2023年成本为12532亿印度卢比(15.20683008亿美元)(2.7%),2028年降至2.4%。在情景3中,根据国家卫生使命(NHM)覆盖40%,成本从2023年的17%变化到2028年的25%。
本研究得出结论,在印度,与OA膝关节的非手术治疗相比,TKR是一种具有成本效益的治疗选择,无论年龄、植入物类型和严重程度如何。